Nuchal Translucency (NT) Screening Calculator

About the Nuchal Translucency (NT) Screening Calculator

First-trimester screening for chromosomal conditions commonly combines the nuchal translucency (NT) ultrasound measurement with maternal age and, in formal combined-screening programs, serum markers such as free β-hCG and PAPP-A. This screening window is between 11 weeks 0 days and 13 weeks 6 days gestation, when the fetal crown-rump length measures 45–84 mm.

The nuchal translucency is the sonolucent space between the skin and soft tissue overlying the cervical spine of the fetus. Increased NT thickness is associated with higher chromosomal-risk estimates and can also be associated with cardiac or other structural findings. Formal FMF-style risk reports use tightly standardized measurement technique, calibrated software, and full marker integration.

This page is a simplified educational worksheet. It uses maternal age priors plus an NT MoM-based likelihood ratio, and it shows an additional trisomy-21 context estimate when absent nasal bone is selected. Biochemistry fields are displayed for note-taking but are not incorporated into the estimate on this page.

When This Page Helps

NT screening remains an important part of first-trimester prenatal assessment because it adds structural context that serum screening and cfDNA do not fully replace. This worksheet helps place an NT value in maternal-age context, but it should not be treated as a substitute for a formal FMF-style report or specialist review.

How to Use the Inputs

1. Enter maternal age at expected delivery date.
2. Enter gestational age in weeks and days (must be 11+0 to 13+6).
3. Enter crown-rump length (CRL) to confirm GA and NT validity window.
4. Enter the NT measurement in millimeters (taken at the widest point).
5. Select nasal bone status if assessed.
6. Optionally enter first-trimester biochemistry (free β-hCG and PAPP-A in MoM) for note-taking; these values are not folded into the estimate on this page.
7. Review the trisomy risk estimates and use them as screening context rather than as diagnosis or a stand-alone follow-up plan.

Example Calculation

Tips & Best Practices

• NT screening is only valid between 11+0 and 13+6 weeks (CRL 45–84 mm).
• Formal NT programs usually rely on FMF or equivalent certification because measurement technique matters as much as the number itself.
• The NT measurement is commonly taken as the largest value from three technically adequate images.
• NT ≥3.5 mm is commonly treated as a threshold for closer specialist review even when the simplified risk number remains lower than expected.
• Combined screening (NT + biochemistry) generally performs better than NT alone; this page does not model the full combined-screen algorithm.
• First- and second-trimester screening strategies are usually interpreted within one coherent screening plan rather than mixed ad hoc.

The Fetal Medicine Foundation (FMF) Algorithm

The most widely used NT screening algorithm was developed by Professor Kypros Nicolaides and the Fetal Medicine Foundation in London. The FMF algorithm uses a Bayesian approach that starts with the patient's age-specific a priori risk and modifies it with likelihood ratios derived from the NT MoM value, free β-hCG MoM, and PAPP-A MoM. The likelihood ratios are calculated from the log-Gaussian distributions of these markers in affected and unaffected pregnancies, with multivariate corrections for correlations between markers. The FMF certifies individual operators and software platforms to ensure quality control.

This page does not reproduce the full FMF combined-screen report. Instead, it provides a simplified NT-centered worksheet so the age prior, NT MoM, and general risk direction remain visible in one place.

Evolution of Prenatal Screening

Prenatal aneuploidy screening has evolved dramatically over four decades. Second-trimester maternal serum screening (triple/quad screen) was the standard from the 1990s through the 2000s, achieving ~70% detection of trisomy 21. First-trimester combined screening (introduced in the early 2000s) improved this to ~85-90%. Cell-free DNA screening, introduced in the early 2010s, can exceed 99% detection for trisomy 21, but at higher cost and without the structural information provided by the NT scan. Guideline statements from ACOG, SMFM, and ACMG support offering some form of screening to pregnant patients, with the specific approach depending on patient preferences, cost, and availability.

NT Beyond Chromosomes: Cardiac and Structural Screening

One of the most important but underrecognized benefits of NT screening is early detection of congenital heart defects (CHD). Fetuses with NT ≥3.5 mm and normal chromosomes have approximately a 5-7% prevalence of major CHD, compared to <1% in the general population. That association is why increased NT often leads to more detailed cardiac and structural review later in pregnancy. The 11-14 week scan can also identify other structural anomalies (anencephaly, body wall defects, megacystis) at a relatively early stage.

Frequently Asked Questions

• What does an increased NT mean?

  An NT measurement above the 95th percentile for gestational age (often around ≥3.5 mm) is associated with higher screening risk for trisomy 21, 18, and 13, Turner syndrome, triploidy, and other chromosomal abnormalities. Increased NT is also associated with structural anomalies including congenital heart defects, diaphragmatic hernia, skeletal dysplasias, and genetic syndromes even when chromosomes are normal. Because of that broader association, an increased NT is usually interpreted in the context of the full ultrasound and the rest of the screening pathway.

• What is the detection rate for Down syndrome screening?

  First-trimester combined screening (NT + biochemistry + maternal age) detects approximately 85-90% of trisomy 21 cases at a 5% false-positive rate. Adding nasal bone assessment increases detection to ~93%. Cell-free DNA (cfDNA/NIPT) has a detection rate of 99%+ with a 0.1% false-positive rate but is still a screening test, not a diagnosis. Definitive diagnosis is usually made with CVS (chorionic villus sampling) at 11-14 weeks or amniocentesis at 15-20 weeks, both of which carry procedure-related risks that have to be discussed in context.

• How do cfDNA and NT screening differ?

  cfDNA (NIPT) is more sensitive and specific for trisomy 21 specifically, but NT screening provides different information. An increased NT can point toward cardiac defects, other chromosomal abnormalities, or genetic syndromes that cfDNA does not directly assess. Many practices use one or both approaches depending on local workflow and patient preference, so this worksheet is best read as part of that broader screening context rather than as a substitute for it.

• How are higher-risk screening results usually interpreted?

  A higher-risk result on first-trimester screening means the screen is positive, not that a diagnosis has been made. Many such results are false positives. Common follow-up discussions may include genetic counseling, cfDNA as a secondary screen, CVS for first-trimester diagnosis, or amniocentesis later in pregnancy. The right next step depends on how much diagnostic certainty is needed, the ultrasound picture, and local specialist guidance.

• How accurate must the NT measurement be?

  NT measurement technique is critical for screening accuracy. Formal NT protocols call for a mid-sagittal fetal view, a neutral fetal position, and calipers placed on the inner edges of the nuchal fold lines perpendicular to the long axis. The reported value is commonly the maximum of three technically adequate images. Inter-operator variability is one of the biggest sources of error, which is why FMF-style programs use operator audit and quality control.

• What happens with NT of 3.5+ mm but normal chromosomes?

  When NT measures ≥3.5 mm but chromosomes are normal, the pregnancy can still carry higher structural-anomaly risk. Detailed fetal echocardiography and anatomy review are commonly discussed because congenital heart defects are the most frequent association. When NT is markedly increased (for example ≥6.5 mm), the conversation may also broaden to include additional genetic testing depending on the rest of the ultrasound findings and the specialist assessment.